Mizuho Securities analyst Difei Yang maintained a Buy rating on Marinus (NASDAQ: MRNS) today and set a price target of $13. The company’s shares closed yesterday at $4.74.
Yang commented:
“We see the upcoming phase 2 results of Ganaxolone IV in severe postpartum depression (PPD) in 3Q18 as the most important catalyst for the company in 2018 and we remain confident ahead of the data readout.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 21.3% and a 51.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
Marinus has an analyst consensus of Moderate Buy, with a price target consensus of $13.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.87 and a one-year low of $1.13. Currently, Marinus has an average volume of 1.06M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E.
Read More on MRNS:
Marinus Pharmaceuticals Inc (MRNS) Wins a Bull Thanks to Potential in Multiple Central Nervous System Indications
